Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 22;17(4):610. doi: 10.3390/ijms17040610

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Smad3 increases the sensitivity of HCC to cisplatin in vivo. SMMC-7721 (A) and HCC-LM3 (B) cells were injected subcutaneously into Balb/c-nu mice and cisplatin was injected i.p. every three days; (C,D) Tumor weight was examined after mice were sacrificed; (E) Subcutaneous tumors were subjected to smad3 and ki67 staining. Representative pictures are shown (100×); (F) The percentage of ki67 stained nuclei was calculated in different groups. All the results are represented as the mean ± S.D. from three independent trials. (*** p < 0.001; n.s. means no significance).

Smad3 increases the sensitivity of HCC to cisplatin in vivo. SMMC-7721 (A) and HCC-LM3 (B) cells were injected subcutaneously into Balb/c-nu mice and cisplatin was injected i.p. every three days; (C,D) Tumor weight was examined after mice were sacrificed; (E) Subcutaneous tumors were subjected to smad3 and ki67 staining. Representative pictures are shown (100×); (F) The percentage of ki67 stained nuclei was calculated in different groups. All the results are represented as the mean ± S.D. from three independent trials. (*** p < 0.001; n.s. means no significance).